vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and Axos Financial, Inc. (AX). Click either name above to swap in a different company.
Axos Financial, Inc. is the larger business by last-quarter revenue ($385.1M vs $284.0M, roughly 1.4× ACADIA PHARMACEUTICALS INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 33.3%, a 63.0% gap on every dollar of revenue. On growth, Axos Financial, Inc. posted the faster year-over-year revenue change (25.1% vs 9.4%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 14.3%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Axos Financial is an American bank holding company based in Las Vegas, Nevada and is the parent of Axos Bank, a direct bank. It also offers registered investment adviser services and an electronic trading platform.
ACAD vs AX — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $385.1M |
| Net Profit | $273.6M | $128.4M |
| Gross Margin | 90.8% | — |
| Operating Margin | 6.1% | 45.6% |
| Net Margin | 96.3% | 33.3% |
| Revenue YoY | 9.4% | 25.1% |
| Net Profit YoY | 90.3% | 22.6% |
| EPS (diluted) | $1.61 | $2.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $385.1M | ||
| Q3 25 | $278.6M | $323.4M | ||
| Q2 25 | $264.6M | $321.4M | ||
| Q1 25 | $244.3M | $308.8M | ||
| Q4 24 | $259.6M | $307.9M | ||
| Q3 24 | $250.4M | $320.7M | ||
| Q2 24 | $242.0M | $290.9M | ||
| Q1 24 | $205.8M | $294.8M |
| Q4 25 | $273.6M | $128.4M | ||
| Q3 25 | $71.8M | $112.4M | ||
| Q2 25 | $26.7M | $110.7M | ||
| Q1 25 | $19.0M | $105.2M | ||
| Q4 24 | $143.7M | $104.7M | ||
| Q3 24 | $32.8M | $112.3M | ||
| Q2 24 | $33.4M | $104.9M | ||
| Q1 24 | $16.6M | $110.7M |
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — | ||
| Q1 24 | 88.8% | — |
| Q4 25 | 6.1% | 45.6% | ||
| Q3 25 | 12.8% | 46.3% | ||
| Q2 25 | 12.2% | 48.5% | ||
| Q1 25 | 7.9% | 47.9% | ||
| Q4 24 | 59.1% | 48.8% | ||
| Q3 24 | 12.6% | 49.6% | ||
| Q2 24 | 12.6% | 49.6% | ||
| Q1 24 | 7.4% | 52.8% |
| Q4 25 | 96.3% | 33.3% | ||
| Q3 25 | 25.8% | 34.7% | ||
| Q2 25 | 10.1% | 34.4% | ||
| Q1 25 | 7.8% | 34.1% | ||
| Q4 24 | 55.4% | 34.0% | ||
| Q3 24 | 13.1% | 35.0% | ||
| Q2 24 | 13.8% | 36.0% | ||
| Q1 24 | 8.0% | 37.6% |
| Q4 25 | $1.61 | $2.22 | ||
| Q3 25 | $0.42 | $1.94 | ||
| Q2 25 | $0.16 | $1.89 | ||
| Q1 25 | $0.11 | $1.81 | ||
| Q4 24 | $0.86 | $1.80 | ||
| Q3 24 | $0.20 | $1.93 | ||
| Q2 24 | $0.20 | $1.75 | ||
| Q1 24 | $0.10 | $1.91 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $1.0B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $2.9B |
| Total Assets | $1.6B | $28.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $1.0B | ||
| Q3 25 | $258.0M | $2.6B | ||
| Q2 25 | $253.6M | $1.9B | ||
| Q1 25 | $217.7M | $2.0B | ||
| Q4 24 | $319.6M | $2.4B | ||
| Q3 24 | $155.1M | $2.6B | ||
| Q2 24 | $177.1M | $2.0B | ||
| Q1 24 | $204.7M | $2.1B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $312.7M | ||
| Q1 25 | — | $377.4M | ||
| Q4 24 | — | $358.7M | ||
| Q3 24 | — | $313.5M | ||
| Q2 24 | — | $325.7M | ||
| Q1 24 | — | $330.4M |
| Q4 25 | $1.2B | $2.9B | ||
| Q3 25 | $917.3M | $2.8B | ||
| Q2 25 | $822.4M | $2.7B | ||
| Q1 25 | $765.2M | $2.6B | ||
| Q4 24 | $732.8M | $2.5B | ||
| Q3 24 | $577.2M | $2.4B | ||
| Q2 24 | $516.7M | $2.3B | ||
| Q1 24 | $464.0M | $2.2B |
| Q4 25 | $1.6B | $28.2B | ||
| Q3 25 | $1.3B | $27.4B | ||
| Q2 25 | $1.2B | $24.8B | ||
| Q1 25 | $1.1B | $24.0B | ||
| Q4 24 | $1.2B | $23.7B | ||
| Q3 24 | $976.9M | $23.6B | ||
| Q2 24 | $914.1M | $22.9B | ||
| Q1 24 | $855.1M | $22.6B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.12× | ||
| Q1 25 | — | 0.14× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.13× | ||
| Q2 24 | — | 0.14× | ||
| Q1 24 | — | 0.15× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $104.1M |
| Free Cash FlowOCF − Capex | — | $85.4M |
| FCF MarginFCF / Revenue | — | 22.2% |
| Capex IntensityCapex / Revenue | — | 4.9% |
| Cash ConversionOCF / Net Profit | -0.18× | 0.81× |
| TTM Free Cash FlowTrailing 4 quarters | — | $695.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $104.1M | ||
| Q3 25 | $74.3M | $118.4M | ||
| Q2 25 | $64.0M | $490.3M | ||
| Q1 25 | $20.3M | $73.7M | ||
| Q4 24 | $40.4M | $162.5M | ||
| Q3 24 | $63.2M | $70.8M | ||
| Q2 24 | $25.0M | $305.5M | ||
| Q1 24 | $29.1M | $115.8M |
| Q4 25 | — | $85.4M | ||
| Q3 25 | $73.9M | $109.3M | ||
| Q2 25 | — | $436.1M | ||
| Q1 25 | — | $65.1M | ||
| Q4 24 | — | $156.4M | ||
| Q3 24 | $63.2M | $53.0M | ||
| Q2 24 | — | $269.5M | ||
| Q1 24 | — | $107.3M |
| Q4 25 | — | 22.2% | ||
| Q3 25 | 26.5% | 33.8% | ||
| Q2 25 | — | 135.7% | ||
| Q1 25 | — | 21.1% | ||
| Q4 24 | — | 50.8% | ||
| Q3 24 | 25.2% | 16.5% | ||
| Q2 24 | — | 92.6% | ||
| Q1 24 | — | 36.4% |
| Q4 25 | — | 4.9% | ||
| Q3 25 | 0.1% | 2.8% | ||
| Q2 25 | — | 16.9% | ||
| Q1 25 | — | 2.8% | ||
| Q4 24 | — | 2.0% | ||
| Q3 24 | 0.0% | 5.5% | ||
| Q2 24 | — | 12.4% | ||
| Q1 24 | — | 2.9% |
| Q4 25 | -0.18× | 0.81× | ||
| Q3 25 | 1.03× | 1.05× | ||
| Q2 25 | 2.40× | 4.43× | ||
| Q1 25 | 1.07× | 0.70× | ||
| Q4 24 | 0.28× | 1.55× | ||
| Q3 24 | 1.93× | 0.63× | ||
| Q2 24 | 0.75× | 2.91× | ||
| Q1 24 | 1.76× | 1.05× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
AX
Segment breakdown not available.
